P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)
Authors
Keywords
-
Journal
Pharmaceuticals
Volume 14, Issue 11, Pages 1087
Publisher
MDPI AG
Online
2021-10-28
DOI
10.3390/ph14111087
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib
- (2021) Yaogeng Wang et al. PHARMACOLOGICAL RESEARCH
- OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation
- (2020) Yaogeng Wang et al. BRITISH JOURNAL OF PHARMACOLOGY
- Advances in Targeting RET-Dependent Cancers
- (2020) Vivek Subbiah et al. Cancer Discovery
- Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry
- (2020) Rahime Şentürk et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib
- (2020) Ezra Y Rosen et al. CLINICAL CANCER RESEARCH
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- (2020) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients with RET -Rearranged Lung Cancers
- (2018) Alexander Drilon et al. Journal of Thoracic Oncology
- A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.
- (2018) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- P-glycoprotein and Breast Cancer Resistance Protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability
- (2018) Wenlong Li et al. PHARMACOLOGICAL RESEARCH
- Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
- (2017) Oliver Gautschi et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation
- (2017) Stéphanie van Hoppe et al. PHARMACOLOGICAL RESEARCH
- Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
- (2017) Kiyotaka Yoh et al. Lancet Respiratory Medicine
- RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
- (2016) Shumei Kato et al. CLINICAL CANCER RESEARCH
- Complete Knockout of Endogenous Mdr1 ( Abcb1 ) in MDCK Cells by CRISPR-Cas9
- (2016) Ivailo Simoff et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
- (2016) Alexander Drilon et al. LANCET ONCOLOGY
- Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy
- (2015) Nilay Thakkar et al. AAPS Journal
- Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer
- (2015) Jun Ho Ji et al. PLoS Genetics
- What do drug transporters really do?
- (2014) Sanjay K. Nigam NATURE REVIEWS DRUG DISCOVERY
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
- (2013) Seng Chuan Tang et al. INTERNATIONAL JOURNAL OF CANCER
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Structure and Physiology of the RET Receptor Tyrosine Kinase
- (2013) C. F. Ibanez Cold Spring Harbor Perspectives in Biology
- Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption
- (2012) Yoshihisa Shitara et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies
- (2011) Megan Roth et al. BRITISH JOURNAL OF PHARMACOLOGY
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel
- (2010) Yong Zhang et al. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
- Membrane transporters in drug development
- (2010) NATURE REVIEWS DRUG DISCOVERY
- Impact of OATP transporters on pharmacokinetics
- (2009) A Kalliokoski et al. BRITISH JOURNAL OF PHARMACOLOGY
- Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family
- (2008) B. Hagenbuch et al. XENOBIOTICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started